Journal article

Plasma apolipoprotein E and Alzheimer disease risk The AIBL study of aging

VB Gupta, SM Laws, VL Villemagne, D Ames, AI Bush, KA Ellis, JK Lui, C Masters, CC Rowe, C Szoeke, K Taddei, RN Martins

Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2011


Funding Acknowledgements

Core funding for the study was provided by CSIRO, which was supplemented by in-kind contributions from the study partners (see Richard Head of CSIRO initiated and facilitated the AIBL collaboration. The study also received support from the National Health and Medical Research Council (NHMRC) via the Dementia Collaborative Research Centres program (DCRC2). Pfizer International has contributed financial support to assist with analysis of blood samples and to further the AIBL research program. The McCusker Foundation has contributed financial and in-kind support to AIBL. Both Veer Bala Gupta and Simon Laws are research fellows at Edith Cowan University. Dr Gupta's salary is fully provided by Alzhyme Pty Ltd. Cassandra Szoeke is partially supported by a research fellowship funded by Alzheimer's Australia. Alzheimer's Australia (Victoria and Western Australia) assisted with promotion of the study and the screening of telephone calls from volunteers.Dr. Gupta and S. M. Laws report no disclosures. Dr. Villemagne serves on the editorial board of the Journal of Alzheimer's Disease; serves as a consultant for Bayer Schering Pharma; and receives research support from NHMRC and NEDO, Japan. Dr. Ames has served on scientific advisory boards for Novartis, Janssen, and Pfizer Inc.; has received funding for travel from Janssen and Pfizer Inc.; serves as Editor-in-Chief for International Psychogeriatrics; receives publishing royalties for Dementia, 3rd ed. (Hodder, 2005); has received speaker honoraria from Pfizer Inc. and Lundbeck Inc.; and receives research support from Eli Lilly and Company, GlaxoSmithKline, Forest Laboratories, Inc., Novartis, and CSIRO. Dr. Bush serves on a scientific advisory board and as a consultant for Prana Biotechnology Ltd.; serves on the editorial board of the Journal of Alzheimer's Disease; is coinventor on a patent re: APP ferroxidase activity; receives research support from Australian Research Council Federation Fellowship and NHMRC; has received license fee payments Neuroptix Corporation for a patent re: Diagnostics for Alzheimer's disease; and holds stock in Prana Biotechnology Ltd. Dr. Ellis, Dr. Lui, and Dr. Masters report no disclosures. Dr. Rowe serves on scientific advisory boards for Bayer Schering Pharma, Elan Corporation, and AstraZeneca; has received speaker honoraria from Bayer Schering Pharma; and receives research support from Bayer Schering Pharma, Avid Radiopharmaceuticals, Inc., CSIRO, and the Alzheimer's Association. Dr. Szoeke has previously been a clinical consultant and received speaker honoraria from Pfizer, SanofiAventis, Mayne Pharma, and Lundbeck; may accrue revenue on a pending patent (filed 2003); has been employed as Commercial Entity Clinical Consultant, Preventive Health, CSIRO Associate Professor, Women's Health Ageing, National Ageing Research Institute, University of Melbourne; research support, government entities: NHMRC, chief investigator, 2009, 2010; academic entities: National Ageing Research Institute, University of Melbourne, Melbourne Health; research support, foundations, and societies: ESA, Epilepsy Fellowship, 2007 Bio21, Pharmacogenetics Overseas Training Scholarship, 2008 RACP, PostDoc Scholarship, 2007 Alzheimer's Association of Australia, Research Fellow, 2008-2010, Scobie and Claire McKinnon Foundation, chief investigator, 2009, Collier Foundations, chief investigator, 2009, and Brain Foundation, chief investigator, 2010. K. Taddei reports no disclosures. Dr. Martins has served on the editorial advisory board of the Journal of Alzheimer's Disease, Senior Editor for 1 year and previously review editor for 3 years; consultancies: consultant to small biotech company, Alzhyme; currently no financial benefits or fees accepted; research support, government entities: CSIRO Flagship funding for 3 years at

million per annum; stock/stock options/board of directors compensation: holds stock for small biotech company, Alzhyme, which is not listed.